M
Manuel Ramos-Casals
Researcher at University of Barcelona
Publications - 340
Citations - 24977
Manuel Ramos-Casals is an academic researcher from University of Barcelona. The author has contributed to research in topics: Lupus erythematosus & Antiphospholipid syndrome. The author has an hindex of 79, co-authored 319 publications receiving 20554 citations. Previous affiliations of Manuel Ramos-Casals include University of California, San Diego & Chartered Institute of Management Accountants.
Papers
More filters
Journal ArticleDOI
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients
Ricard Cervera,Munther A. Khamashta,Josep Font,Gian Domenico Sebastiani,Antonio Gil,Lavilla P,Juan Carlos Mejía,A. Olcay Aydintug,Hanna Chwalinska-Sadowska,Enrique de Ramón,Antonio Fernández-Nebro,Mauro Galeazzi,Merete Valen,Alessandro Mathieu,Frédéric Houssiau,Natividad Caro,Paula Alba,Manuel Ramos-Casals,Miguel Ingelmo,Graham R. V. Hughes +19 more
TL;DR: In this paper, the authors assessed the frequency and characteristics of the main causes of morbidity and mortality in systemic lupus erythematosus (SLE) during a 10-year period and compared the frequency of early manifestations with those that appeared later in the evolution of the disease.
Journal ArticleDOI
Adult haemophagocytic syndrome
Manuel Ramos-Casals,Pilar Brito-Zerón,Armando López-Guillermo,Munther A. Khamashta,Xavier Bosch +4 more
TL;DR: Analysis of the genetic and molecular pathophysiology of these syndromes have improved the understanding of the crosstalk between lymphocytes and histiocytes and their regulatoty mechanisms, and it is essential to initiate appropriate treatment and improve the quality of life and survival of patients with this challenging disorder.
Journal ArticleDOI
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
TL;DR: High levels of evidence were found that AMs prevent lupus flares and increase long-term survival of patients with SLE; moderate evidence of protection against irreversible organ damage, thrombosis and bone mass loss and evidence supporting an effect on severe l upus activity, lipid levels and subclinical atherosclerosis was weak.
Journal ArticleDOI
Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.
Manuel Ramos-Casals,P. Brito-Zerón,Sandra Muñoz,Natalia Soria,Diana Galiana,Laura Bertolaccini,M J Cuadrado,Munther A. Khamashta +7 more
TL;DR: The use of anti-TNF agents has been associated with an increasing number of cases of autoimmune diseases, principally cutaneous vasculitis, lupus-like syndrome, SLE, and interstitial lung disease.
Journal ArticleDOI
Immune-related adverse events of checkpoint inhibitors.
Manuel Ramos-Casals,Julie R. Brahmer,Margaret K. Callahan,Margaret K. Callahan,Alejandra Flores-Chávez,Niamh M. Keegan,Munther A. Khamashta,Olivier Lambotte,Xavier Mariette,Aleix Prat,Maria E. Suarez-Almazor +10 more
TL;DR: This Primer by Ramos-Casals and colleagues summarizes the epidemiology, mechanisms, diagnosis and treatment of immune-related adverse events and should be prescribed carefully to reduce the potential of short-term and long-term complications.